title: Interactions between dopamine and GABA in the control of ambulatory activity.
abstract: Ambulatory activity of male rats was quantified in an open field. The subjects were treated with DL-amphetamine and amfonelic acid alone or combined with the GABA transaminase inhibitors gamma-acetylen GABA (GAG) and sodium valproate as well as with the GABAA agonist THIP and the GABAB agonist baclofen. Subeffective doses of the GABAergic drugs did not modify the effects of moderate doses of the dopaminergic stimulants whereas effective doses continued to reduce ambulatory activity just as in the absence of dopaminergic activation. When DL-amphetamine or amfonelic acid were administered in doses that strongly enhanced ambulatory activity, doses of the GABAergic drugs that were inhibitory in the absence of dopaminergic stimulation were no longer effective. The mixed D1/D2 dopamine antagonist pimozide, the D1 antagonist SCH 23390 and the D2 antagonist sulpiride were then combined with subeffective doses of the GABA agonists. GAG, sodium valproate and baclofen were potentiated by pimozide and SCH 23390 but not by sulpiride. THIP was ineffective. These data show that GABAergic drugs had a reduced effect after stimulation of dopaminergic neurotransmission. On the other hand, when dopamine D1 receptors were blocked, nonselective GABA agonists and the GABAB agonist baclofen were potentiated. This was not the case for the GABAA agonist THIP, suggesting that the GABAA receptor is of slight importance for the interactions between GABA and dopamine in the control of ambulatory activity. No potentiation of GABAergic agonists was obtained after treatment with a dopamine D2 antagonist.
authors.affiliation: Laboratoire de Psychophysiologie, Faculté des Sciences, Université de Tours, France.
authors.forename: A
authors.initials: A
authors.lastname: Agmo
authors.forename: C
authors.initials: C
authors.lastname: Belzung
authors.forename: M
authors.initials: M
authors.lastname: Giordano
mesh_terms: D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors*; D000480:Alkynes; D000614:Aminocaproates / Q000494:pharmacology; D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018682:GABA Agents / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D014635:Valproic Acid / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D000480:Alkynes; D000614:Aminocaproates; D018492:Dopamine Antagonists; D004791:Enzyme Inhibitors; D018682:GABA Agents; D005680:gamma-Aminobutyric Acid; C013785:4-amino-5-hexynoic acid; D014635:Valproic Acid; D000612:4-Aminobutyrate Transaminase; D004298:Dopamine